Cargando…
Inhibition of Bcl6b promotes gastric cancer by amplifying inflammation in mice
BACKGROUND: Chronic gastritis has been demonstrated to be a key cause of gastric cancer (GC), and control of gastric inflammation is regarded as an effective treatment for the clinical prevention of gastric carcinogenesis. However, there remains an unmet need to identify the dominant regulators of g...
Autores principales: | Cai, Wang-Yu, Lin, Ling-Yun, Wang, Lin, Yang, Li, Ye, Guo-Dong, Zeng, Qiang, Cheng, Jia, Xie, Yuan-Yuan, Chen, Mao-Li, Luo, Qi-Cong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617686/ https://www.ncbi.nlm.nih.gov/pubmed/31288844 http://dx.doi.org/10.1186/s12964-019-0387-6 |
Ejemplares similares
-
Tumor-originated exosomal lncUEGC1 as a circulating biomarker for early-stage gastric cancer
por: Lin, Ling-Yun, et al.
Publicado: (2018) -
Bcl‐2/Bcl‐xl inhibitor APG‐1252‐M1 is a promising therapeutic strategy for gastric carcinoma
por: Yi, Hanjie, et al.
Publicado: (2020) -
Bcl-3: A Double-Edged Sword in Immune Cells and Inflammation
por: Liu, Hui, et al.
Publicado: (2022) -
JQ1 synergizes with the Bcl-2 inhibitor ABT-263 against MYCN-amplified small cell lung cancer
por: Wang, Huogang, et al.
Publicado: (2017) -
High-Grade B-Cell Lymphoma (HGBL) with MYC and BCL2 and/or BCL6 Rearrangements Is Predominantly BCL6-Rearranged and BCL6-Expressing in Taiwan
por: Tsai, Cheng-Chih, et al.
Publicado: (2021)